Page 1281 - Williams Hematology ( PDFDrive )

1256 Part IX: Lymphocytes and Plasma Cells Chapter 81: Hematologic Manifestations of Acquired Immunodeficiency Syndrome 1257

89. French MA: HIV/AIDS: Immune reconstitution inflammatory syndrome: A reap- 117. Chiao EY, Dezube BJ, Krown SE, et al: Time for oncologists to opt in for routine opt-out
praisal. Clin Infect Dis 48:101–107, 2009. HIV testing? JAMA 304:334–339, 2010.
90. Grant PM, Komarow L, Andersen J, et al: Risk factor analyses for immune reconstitu- 118. Shiels MS, Pfeiffer RM, Hall HI, et al: Proportions of Kaposi sarcoma, selected non
tion inflammatory syndrome in a randomized study of early vs. deferred ART during -Hodgkin lymphomas, and cervical cancer in the United States occurring in persons
an opportunistic infection. PLoS One 5:e11416, 2010. with AIDS, 1980–2007. JAMA 305:1450–1459, 2011.
91. Lawn SD, Myer L, Bekker LG, et al: Tuberculosis-associated immune reconstitution dis- 119. Liapis K, Clear A, Owen A, et al: The microenvironment of AIDS-related diffuse large
ease: Incidence, risk factors and impact in an antiretroviral treatment service in South B-cell lymphoma provides insight into the pathophysiology and indicates possible ther-
Africa. AIDS 21:335–341, 2007. apeutic strategies. Blood 122:424–433, 2013.
92. Muller M, Wandel S, Colebunders R, et al: Immune reconstitution inflammatory syn- 120. Gloghini A, Dolcetti R, Carbone A: Lymphomas occurring specifically in HIV-infected
drome in patients starting antiretroviral therapy for HIV infection: A systematic review patients: From pathogenesis to pathology. Semin Cancer Biol 23:457–467, 2013.
and meta-analysis. Lancet Infect Dis 10:251–261, 2010. 121. Coutinho R, Pria AD, Gandhi S, et al: HIV status does not impair the outcome of
93. Robertson J, Meier M, Wall J, et al: Immune reconstitution syndrome in HIV: Validat- patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the
ing a case definition and identifying clinical predictors in persons initiating antiretrovi- cART era. AIDS 28:689–697, 2013.
ral therapy. Clin Infect Dis 42:1639–1646, 2006. 122. Tirelli U, Spina M, Gaidano G, et al: Epidemiological, biological and clinical features
94. Achenbach CJ, Harrington RD, Dhanireddy S, et al: Paradoxical immune reconstitution of HIV-related lymphomas in the era of highly active antiretroviral therapy. AIDS
inflammatory syndrome in HIV-infected patients treated with combination antiretro- 14:1675–1688, 2000.
viral therapy after AIDS-defining opportunistic infection. Clin Infect Dis 54:424–433, 123. Hegde U, Filie A, Little RF, et al: High incidence of occult leptomeningeal disease
2012. detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for
95. Meintjes G, Wilkinson RJ, Morroni C, et al: Randomized placebo-controlled trial of central nervous system involvement: The role of flow cytometry versus cytology. Blood
prednisone for paradoxical tuberculosis-associated immune reconstitution inflamma- 105:496–502, 2005.
tory syndrome. AIDS 24:2381–2390, 2010. 124. Kaplan LD, Straus DJ, Testa MA, et al: Low-dose compared with standard-dose
96. Hall HI, Song R, Rhodes P, et al: Estimation of HIV incidence in the United States. m-BACOD chemotherapy for non-Hodgkin’s lymphoma associated with human
JAMA 300:520–529, 2008. immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases
97. Marks G, Crepaz N, Senterfitt JW, et al: Meta-analysis of high-risk sexual behav- AIDS Clinical Trials Group. N Engl J Med 336:1641–1648, 1997.
ior in persons aware and unaware they are infected with HIV in the United States: 125. Lim ST, Karim R, Tulpule A, et al: Prognostic factors in HIV-related diffuse large-
Implications for HIV prevention programs. J Acquir Immune Defic Syndr 39:446–453, cell lymphoma: Before versus after highly active antiretroviral therapy. J Clin Oncol
2005. 23:8477–8482, 2005.
98. Crepaz N, Lyles CM, Wolitski RJ, et al: Do prevention interventions reduce HIV risk 126. Little RF, Pittaluga S, Grant N, et al: Highly effective treatment of acquired immunode-
behaviours among people living with HIV? A meta-analytic review of controlled trials. ficiency syndrome-related lymphoma with dose-adjusted EPOCH: Impact of antiretro-
AIDS 20:143–157, 2006. viral therapy suspension and tumor biology. Blood 101:4653–4659, 2003.
99. Lyles CM, Kay LS, Crepaz N, et al: Best-evidence interventions: Findings from a 127. Sparano JA, Lee JY, Kaplan LD, et al: Rituximab plus concurrent infusional EPOCH
systematic review of HIV behavioral interventions for US populations at high risk, chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.
2000–2004. Am J Public Health 97:133–143, 2007. Blood 115:3008–3016, 2010.
100. Gray RH, Kigozi G, Serwadda D, et al: Male circumcision for HIV prevention in men in 128. Dunleavy K, Little RF, Pittaluga S, et al: The role of tumor histogenesis, FDG-PET, and
Rakai, Uganda: A randomised trial. Lancet 369:657–666, 2007. short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated
101. Connor EM, Sperling RS, Gelber R, et al: Reduction of maternal-infant transmission diffuse large B-cell lymphoma. Blood 115:3017–3024, 2010.
of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS 129. Kaplan LD, Lee JY, Ambinder RF, et al: Rituximab does not improve clinical outcome
Clinical Trials Group Protocol 076 Study Group. N Engl J Med 331:1173–1180, 1994. in a randomized phase 3 trial of CHOP with or without rituximab in patients with
102. Guay LA, Musoke P, Fleming T, et al: Intrapartum and neonatal single-dose nevirapine HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.
compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Blood 106:1538–1543, 2005.
Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354:795–802, 1999. 130. Ribera JM, Oriol A, Morgades M, et al: Safety and efficacy of cyclophosphamide, Adri-
103. Baeten JM, Donnell D, Ndase P, et al: Antiretroviral prophylaxis for HIV prevention in amycin, vincristine, prednisone and rituximab in patients with human immunodefi-
heterosexual men and women. N Engl J Med 367:399–410, 2012. ciency virus-associated diffuse large B-cell lymphoma: Results of a phase II trial. Br J
104. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al: Effectiveness and safety of teno- Haematol 140:411–419, 2008.
fovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. 131. Wyen C, Jensen B, Hentrich M, et al: Treatment of AIDS-related lymphomas: Rituxi-
Science 329:1168–1174, 2010. mab is beneficial even in severely immunosuppressed patients. AIDS 26:457–464, 2012.
105. Karim SS, Kashuba AD, Werner L, et al: Drug concentrations after topical and oral 132. Levine AM, Noy A, Lee JY, et al: Pegylated liposomal doxorubicin, rituximab, cyclo-
antiretroviral pre-exposure prophylaxis: Implications for HIV prevention in women. phosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malig-
Lancet 378:279–281, 2011. nancy Consortium Study 047. J Clin Oncol 31:58–64, 2013.
106. Chun TW, Carruth L, Finzi D, et al: Quantification of latent tissue reservoirs and total 133. Barta SK, Lee JY, Kaplan LD, et al: Pooled analysis of AIDS malignancy consortium
body viral load in HIV-1 infection. Nature 387:183–188, 1997. trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-as-
107. Finzi D, Blankson J, Siliciano JD, et al: Latent infection of CD4+ T cells provides a sociated non-Hodgkin lymphoma. Cancer 118:3977–3983, 2012.
mechanism for lifelong persistence of HIV-1, even in patients on effective combination 134. Barta SK, Xue X, Wang D, et al: Treatment factors affecting outcomes in HIV-associated
therapy. Nat Med 5:512–517, 1999. non-Hodgkin lymphomas: A pooled analysis of 1546 patients. Blood 122:3251–3262,
108. Siliciano JD, Kajdas J, Finzi D, et al: Long-term follow-up studies confirm the stability 2013.
of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9:727–728, 2003. 135. Zhong DT, Shi CM, Chen Q, et al: Study on effectiveness of gemcitabine, dexametha-
109. Hutter G, Nowak D, Mossner M, et al: Long-term control of HIV by CCR5 Delta32/ sone, and cisplatin (GDP) for relapsed or refractory AIDS-related non-Hodgkin’s lym-
Delta32 stem-cell transplantation. N Engl J Med 360:692–698, 2009. phoma. Ann Hematol 91:1757–1763, 2012.
109A. Shan L, Deng K, Shroff Neeta S, et al. Stimulation of HIV-1-Specific Cytolytic T Lym- 136. Bi J, Espina BM, Tulpule A, et al: High-dose cytosine-arabinoside and cisplatin regi-

phocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation. mens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin’s lym-
Immunity 36(3):491-501, 2012. phoma. J Acquir Immune Defic Syndr 28:416–421, 2001.
110. Tebas P, Stein D, Binder-Scholl G, et al: Antiviral effects of autologous CD4 T cells 137. Gopal S, Patel MR, Yanik EL, et al: Temporal trends in presentation and survival
genetically modified with a conditionally replicating lentiviral vector expressing long for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst
antisense to HIV. Blood 121:1524–1533, 2013. 105:1221–1229, 2013.
111. Tebas P, Stein D, Tang WW, et al: Gene editing of CCR5 in autologous CD4 T cells of 138. Costa LJ, Xavier AC, Wahlquist AE, et al: Trends in survival of patients with Burkitt
persons infected with HIV. N Engl J Med 370:901–910, 2014. lymphoma/leukemia in the USA: An analysis of 3691 cases. Blood 121:4861–4866,
112. Work Group for HIV and Aging Consensus Project: Summary report from the Human 2013.
Immunodeficiency Virus and Aging Consensus Project: Treatment strategies for clini- 139. Dolcetti R, Dal Col J, Martorelli D, et al: Interplay among viral antigens, cellular path-
cians managing older individuals with the human immunodeficiency virus. J Am Geri- ways and tumor microenvironment in the pathogenesis of EBV-driven lymphomas.
atr Soc 60:974, 2012. Semin Cancer Biol 23:441–456, 2013.
113. Deeks SG, Lewin SR, Havlir DV: The end of AIDS: HIV infection as a chronic disease. 140. Lim ST, Karim R, Nathwani BN, et al: AIDS-related Burkitt’s lymphoma versus dif-
Lancet 382:1525–1533, 2013. fuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and
114. Powles T, Robinson D, Stebbing J, et al: Highly active antiretroviral therapy and the HAART eras: Significant differences in survival with standard chemotherapy. J Clin
incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol Oncol 23:4430–4438, 2005.
27:884–890, 2009. 141. Galicier L, Fieschi C, Borie R, et al: Intensive chemotherapy regimen (LMB86) for St
115. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996– Jude stage IV AIDS-related Burkitt lymphoma/leukemia: A prospective study. Blood
2006: Collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 50:1387–1396, 2010. 110:2846–2854, 2007.
116. Campsmith ML, Rhodes PH, Hall HI, et al: Undiagnosed HIV prevalence among adults 142. Xicoy B, Ribera JM, Miralles P, et al: Comparison of CHOP treatment with specific
and adolescents in the United States at the end of 2006. J Acquir Immune Defic Syndr short-intensive chemotherapy in AIDS-related Burkitt’s lymphoma or leukemia. Med
53:619–624, 2010. Clin (Barc) 136:323–328, 2011.

Kaushansky_chapter 81_p1239-1260.indd 1256 9/21/15 11:19 AM